CoChat

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time

Open access
Kumar, S K, Dispenzieri, A, Fraser, R, Mingwei, F, Akpek, G, Cornell, R, Kharfan-Dabaja, M, Freytes, C, Hashmi, S, Hildebrandt, G, Holmberg, L, Kyle, R, Lazarus, H, Lee, C, Mikhael, J, Nishihori, T, Tay, J, Usmani, S, Vesole, D, Vij, R, Wirk, B, Krishnan, A, Gasparetto, C, Mark, T, Nieto, Y, Hari, P, D'Souza, A · 2018 · Leukemia
Cited by 92

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We hypothesized that new drug classes and combinations employed prior to AHCT as well as after post-AHCT relapse may have changed the natural history of MM in this population. We analyzed the Center for International Blood and Marrow Transplant Research database to track overall survival (OS) of MM patients receiving single AHCT within 12 months after diagnosis (N=3256) and relapsing early post-AHCT (<24 months), and to identify factors predicting for early vs late relapses (24−48 months post-AHCT). Over three periods (2001–2004, 2005–2008, 2009–2013), patient characteristics were balanced except for lower proportion of Stage III, higher likelihood of one induction therapy with novel triplets and higher rates of planned post-AHCT maintenance over time. The proportion of patients relapsing early was stable over time at 35–38%. Factors reducing risk of early relapse included lower stage, chemosensitivity, transplant after 2008 and post-AHCT maintenance. Shorter post-relapse OS was associated with early relapse, IgA MM, Karnofsky <90, stage III, >1 line of induction and lack of maintenance. Post-AHCT early relapse remains a poor prognostic factor, even though outcomes have improved over time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2017.331

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 23

  1. Laubach J, Kumar S . Management of transplant-eligible patients with newly diagnosed multiple myeloma. Cancer Treat Res 2016; 169: 145–167. · DOI
  2. Costa LJ, Zhang M-J, Zhong X, Dispenzieri A, Lonial S, Krishnan A et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 1615–1624. · DOI
  3. Hari PN, McCarthy PL . Multiple myeloma: future directions in autologous transplantation and novel agents. Biol Blood Marrow Transplant 2013; 19: S20–S25. · DOI
  4. Schiffer CA, Zonder JA . Transplantation for myeloma—now or later? N Engl J Med 2017; 376: 1378–1379. · DOI
  5. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128. · DOI · Paper page
  6. D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M et al. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. Leukemia 2017; 31: 1998–2000. · DOI
  7. Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V . Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant 2015; 50: 204–208. · DOI
  8. Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia 2016; 30: 2208–2213. · DOI
  9. Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I et al. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer 2007; 110: 824–829. · DOI
  10. Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant 2008; 42: 413–420. · DOI
  11. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant 2013; 19: 760–766. · DOI
  12. Dispenzieri A . Myeloma: management of the newly diagnosed high-risk patient. Hematology Am Soc Hematol Educ Program 2016; 2016: 485–494. · DOI
  13. Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood 2015; 126: 1996–2004. · DOI
  14. Lonial S, Boise LH, Kaufman J . How I treat high-risk myeloma. Blood 2015; 126: 1536–1543. · DOI
  15. Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D et al. Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis. Biol Blood Marrow Transplant 2016; 22: 1893–1899. · DOI
  16. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016; 127: 2955–2962. · DOI · Paper page
  17. Voorhees PM, Usmani SZ . The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy. Clin Adv Hematol Oncol 2016; 14: 719–728.
  18. McCarthy PL, Einsele H, Attal M, Giralt S . The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. Exp Rev Hematol 2014; 7: 55–66. · DOI
  19. Krishnan A, Vij R, Keller J, Dhakal B, Hari P . Moving beyond autologous transplantation in multiple myeloma: consolidation, maintenance, allogeneic transplant, and immune therapy. Am Soc Clin Oncol Educ Book 2016; 35: 210–221. · DOI
  20. Mohty M, Richardson PG, McCarthy PL, Attal M . Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? Bone Marrow Transplantation 2015; 50: 1024–1029. · DOI
  21. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 2014; 32: 2712–2717. · DOI · Paper page
  22. Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 2014; 28: 690–693. · DOI · Paper page
  23. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc 2013; 88: 360–376. · DOI · Paper page

Cited by

See all 92

Metadata

Authors
Kumar, S. K., Dispenzieri, A., Fraser, R., Mingwei, F., Akpek, G., Cornell, R., Kharfan-Dabaja, M., Freytes, C., Hashmi, S., Hildebrandt, G., Holmberg, L., Kyle, R., Lazarus, H., Lee, C., Mikhael, J., Nishihori, T., Tay, J., Usmani, S., Vesole, D., Vij, R., Wirk, B., Krishnan, A., Gasparetto, C., Mark, T., Nieto, Y., Hari, P., & D'Souza, A.
Venue
Leukemia
Published
2017-11-16
Volume
32
Issue
4
Pages
986-995
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2774700270
Cited by
92
References
10
FWCI
4.89
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.